Targeting Trends Newsletter 04q4

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • An afternoon in the park… (page 2)
  • Venice Watercolor (page 2)
  • SfN meeting in San Diego (page 6)
  • CCK-SAP, NPY-SAP, Anti-M-ZAP, and new antibodies (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

Effects of IB4-SAP on Bladder Overactivity – read article (continued on page 6)

Contributed by Dr. Naoki Yoshimura, Dept Urology/Pharmacology, Univ Pittsburgh School of Medicine, Pittsburgh PA 15213. Dr. Yoshimura summarizes his work with IB4-SAP. A complete report was published in Eur J Neurosci 20(2):474-482, 2004.

Product information related to cover article: IB4-SAP (Cat. #IT-10)

Take Me Out to the Ballgame…

Accomplished Scientist. . . Talented Artist – Rosalind Ridley

  • Palazzo Barbaro

Recent Scientific References – read online

Targeting Talk: Effective Toxins

  • Why do your directions for SSP-SAP state that it is to be used within hours after dissolution? To my knowledge, both proteins and peptides are stable in clean solution.
  • I understand that theoretically only one molecule of Saporin taken up by a cell is enough to induce cell death. I have been looking for literature on this topic but have not come across anything.

Targeting Teaser Solution and Winners

Effects of IB4-SAP on Bladder Overactivity – read article (continued from page 1)

Upcoming Events

  • Society for Neuroscience; October 23-27, 2004; San Diego, CA; Booth 3117
  • The American Society for Cell Biology; December 4-8, 2004; Washington, DC; Booth 403

The Society for Neuroscience meeting comes to San Diego October 23-27

Targeting Tools: Featured Products

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 04q3

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • SP-SAP update (page 2)
  • Venice Watercolor (page 2)
  • Golf at Torrey Pines (page 6)
  • Acetylated LDL-SAP, FITC-labeled second antibodies (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

The Discovery of Saporin – read article (continued on page 6)

Contributed by Dr. Fiorenzo Stirpe, Dipartimento di Patologia sperimentale, Università di Bologna, I-40125 Bologna, Italy

Product information related to cover article: Saporin (Cat. #PR-01)

SAP Facts

Drug Development Update – read article

Accomplished Scientist. . . Talented Artist – Rosalind Ridley

  • Doorway of Campo Sant’Angelo

Recent Scientific References – read online

Targeting Talk: Eliminating CBF Neurons – read online

  • What dosage of 192-Saporin should be used in the lateral ventricle to eliminate cholinergic neurons in the basal forebrain, including substantia innominata (SI)? I read that Calza et al (1) used 2 or 3 micrograms/4.5 ul and found this was highly effective.
  • Should we expect to be able to kill all or almost all ChAT SI neurons?
  • Is there another toxin that will eliminate the remaining ChAT SI neurons?

Upcoming Events

Targeting Teaser Solution and Winners

The Discovery of Saporin – read article (continued from page 1)

Golf Torrey Pines this October! (CANCELLED)

Targeting Tools: Featured Products

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 04q2

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • 10th Anniversary (page 2)
  • San Marco Watercolor (page 2)
  • Streptavidin vs. Avidin (page 5)
  • mu p75-SAP, Anti-Tac-SAP (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

192 IgG-Saporin-Induced Lesions Identify an Inhibitory Role in Cocaine Reward for Cholinergic Neuronal Systems in the Diagonal Band and Ventral Pallidum – read article
(continued on page 6)

Contributed by Dr. James Smith, Wake Forest University School of Medicine, Department of Physiology and Pharmacology, Medical Center Blvd, Winston-Salem NC 27157

Product information related to cover article: 192-IgG-SAP (Cat. #IT-01)

Ten Years and Growing Strong

Accomplished Scientist. . . Talented Artist – Rosalind Ridley

  • Doors of San Marco basilica (watercolor)

Recent Scientific References – read online

Targeting Talk: Streptavidin versus Avidin – read online

  • I recently tried to order avidinylated-SAP and was told that this product has been replaced with a new product, streptavidin-SAP (streptavidin-ZAP). Why did you replace avidinylated-SAP?
  • I use avidinylated-SAP to demonstrate that my antibody internalizes. It worked quite well for me.

192 IgG-Saporin-Induced Lesions Identify an Inhibitory Role in Cocaine Reward – read article
(continued from page 1)

Targeting Tools: Featured Products

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 04q1

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights 

  • 2003 SfN Poster Winner/Runners up (page 2)
  • Dr. Rosalind Ridley (page 2)
  • Not the Right Stuff (page 5)
  • Somatostatin receptor antibodies (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

Cholinergic Deafferentation of the Entorhinal Cortex Impairs Working Memory for Novel, but not Familiar Stimuli in a Delayed Non-Match to Sample (DNMS) Task. – read article
(continued on page 6)

Contributed by ATS’s 2003 Society for Neuroscience Poster of the Year Award Winner: Dr. Jill McGaughy, Boston University, 64 Cummington St., Boston, MA 02215
(see companion story on page 2)

Product information related to cover article: 192-IgG-SAP (Cat. #IT-01)

ATS Gets New Facility for SP-SAP Production – read article

Accomplished Scientist. . . Talented Artist – Rosalind Ridley

  • Duomo in Prato (watercolor)

Targeting Teaser Winners

ATS’s 2003 SfN Poster Award (read winning abstract)

Recent Scientific References – read online

Targeting Talk: Not the Right Stuff – read online

  • Are all lots of 192-Saporin (192-IgG-SAP) the same?
  • How do I find out the optimal dosage?
  • What happens if I use too much immunotoxin

Cholinergic Deafferentation of the Entorhinal Cortex – read article
(continued from page 1)

Targeting Tools: Featured Products

Somatostatin receptor targetingread article

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 03q4

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • “Surfboards for Spinal Cords” (page 2)
  • $2.4M drug devel grant for SP-SAP (page 2)
  • CCK-SAP binding studies (page 5)
  • Rat-ZAP, the newest Second Immunotoxin (Secondary Conjugate) (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

Subplate Neurons and Functional Maturation of Thalamocortical Synapses – read article
(continued on page 6)

Contributed by Dr. Patrick O. Kanold, Dept Neurobiology, Harvard Medical School, Boston, MA 02115. Dr. Kanold summarizes his work with ME20.4-SAP. A complete report was published in Science 301:521-525.

Product information related to cover article: ME20.4-SAP (Cat. #IT-15)

Surfboards for Spinal Cords, September 27 in Ocean Beach, CA

ATS Receives $2.4 M Award for SP-SAP Drug Development (read Press Release)

Recent Scientific References – read online

Targeting Tests: CCK-SAP in Binding Studies – read article

Our thanks to Drs. Frank Porecca, Victory Hruby and Josephine Lai, Department of Pharmacology, The University of Arizona Health Sciences Center for sharing the results of their studies.

Product information related to article: CCK-SAP (Cat. #IT-31)

Subplate Neurons and Functional Maturation of Thalamocortical Synapses – read article
(continued from page 1)

Targeting Teaser Winners from last issue

Targeting Tools: Featured Products

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 03q3

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • Dr. Rania Siam joins ATS team (page 2)
  • SP-SAP update (page 2)
  • Dosing, Volume & Animal Care (page 5)
  • Targeting Dopamine Transporter (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

A New Immunotoxin for Targeting Dopaminergic Neurons

Targeting results with anti-DAT-SAP shown in the Figure are reprinted by permission of Kluwer Academic/Plenum Publishers.The original was published in Cell Mol Neurobiol 23:839-850,2003.

Product information related to cover article: Anti-DAT-SAP (Cat. #IT-25)

Dr. Rania Siam Joins ATS Team of Scientists

Substance P-Saporin (SP-SAP) Drug Development Update

Recent Scientific References

Targeting Talk: Dosing, Volume, and Animal Care

  • When performing intraparenchymal injections of immunotoxin, what is the proper volume to use? Is it better to induce two half-portions per hemisphere or is a higher concentration better? At what concentration do you expect necrosis or inflammation
  • I have been doing research with 192-Saporin for 2-3 years now. I have read in the literature that animals with cholinergic lesions often get sick following surgery and require potatoes, apples, lettuce and saline injections. They may even stop eating or drinking all together. I have followed these practices in the past, but stopped when it didn’t seem to make a difference. (I use a very small insignificant dose that is not prone to make animals ill). This is the first death I have had even remotely possibly related to the toxin. In short, the animal lost 64 grams over a period of 2 weeks, and expired 1-2 days thereafter. I weighed her at death and she was 139 grams (91 gram difference from her initial surgery weight). The rats in our colony are fed and given water ad libitum. However, we think that she dehydrated. She was given the same dose (1.1 microliters) as all of the other rats in the experiment. I do have other rats that were given injections from the same lot that do not appear to be sick or losing weight. I’m not sure what you can do with this information, but I would be grateful for whatever help you can offer.
  • Another one of my 192-Saporin-treated rats is having an adverse reaction, including paralysis of the lower extremities. She has lost 40 grams in the past 3-4 days. Could this be Purkinje cell damage; does that happen after five weeks?

Targeting Teaser Winners from last issue

Targeting Tools: Targeting Dopamine Transporter

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 03q2

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • Funding Awarded (page 2)
  • Retrograde Transport (page 5)
  • Avidinylated-SAP (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

Biotinylated targeting: A viable option? (continued on page 6)

For the IB4-SAP illustration (Figure 1), our thanks to Christopher N. Honda, Ph.D., Associate Professor, Department of Neuroscience, University of Minnesota, 6-145 Jackson Hall, 321 Church Street, Minneapolis, MN 55455

Product information related to cover article: IB4-SAP (Cat. #IT-10), Biotinylation Service

Funding Awarded for SBIR Phase II Grant

Malia and Sam Kohls: Has it been a YEAR already?

Targeting Tickler

Recent Scientific References

Targeting Talk: Retrograde Transport

  • I’m interested in using SAP to eliminate cells through retrograde transport, like OX7-SAP and IB4-SAP have been used. Can you explain how retrograde transport works and if it is possible for this to work with dermorphin-SAP? What determines whether a targeted toxin will be able to be used in retrograde transport?
  • If a targeted toxin cannot be used in retrograde transport, will it only kill cell bodies in the injection site or will it also kill terminals?

Targeting Teaser Winners from last issue

Targeting Tools: Featured Products

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 03q1

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • SP-SAP update (page 2)
  • Custom Conjugations (page 5)
  • Dermorphin-SAP and Fluorescent Conjugates (page 7)

[fivecol_one]Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 [/fivecol_one][fivecol_four_last]

Deep Lumbar Neurons Control Ejaculation (continued on page 6)

Contributed by William Truitt, PhD, Department of Cell Biology, Neurobiology, and Anatomy, Neuroscience Graduate Program, University of Cincinnati, College of Medicine, Post Office Box 670521, Cincinnati, OH 45267-0521, USA.

Product information related to cover article: SSP-SAP, Cat. #IT-11

2002 Society for Neuroscience ATS Award Winner

SP-SAP as a Chronic Pain Therapeutic: An Update

Scientists Present Innovative Results Using ATS Products

Recent Scientific References

Targeting Talk: Custom Peptide-Saporin Conjugates

  • How do I know my peptide will work as a targeted toxin?
  • How much peptide do I need to provide for a custom conjugation?
  • How much of the saporin conjugate will that give me?
  • What is the ratio of saporin to antibody?
  • What quality control is involved?
  • What is the cost of a custom targeted toxin preparation? How long will it take to complete?

Deep Lumbar Neurons Control Ejaculation (continued from page 1)

Targeting Teaser Winners from last issue

Targeting Tools: Featured Products

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 02q4

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • Custom Conjugations (page 2)
  • Abstracts from FENS (page 5)
  • Abstracts from IASP (page 5)
  • anti-SERT-SAP (page 7)

[fivecol_one]Page 1Page 2Page 3Page 4Page 5Page 6Page 7Page 8[/fivecol_one][fivecol_four_last]

Does 192-IgG-Saporin or 5,7-DHT kill cognitive functions in the rat? (continued on page 6)

Contributed by Jean-Christophe Cassel, PhD, Laboratoire de Neurosciences Cognitives et Comportementales, UMR 7521 Université Louis Pasteur/CNRS, Strasbourg, France & Institut für Experimentelle und Klinische Pharmakologie und Toxikologie der Universität Freiburg, Neuropharmakologisches Labor, Freiburg, Germany. Dr. Cassel and colleagues are the authors of four publications released this quarter using 192-Saporin.

Product information related to cover article: 192-IgG-SAP (Cat. #IT-01)

SP-SAP Efficacy Reported at IASP 10th World Congress on Pain

Targeting Talk: Custom Antibody-Saporin conjugates

  • How do I know my antibody will work in an immunotoxin?
  • How much antibody do I need to provide for a custom conjugation?
  • How much of the saporin conjugate will that give me?
  • What is the ratio of saporin to antibody?
  • What quality control is involved? Will you provide product specifications such as average saporin to antibody ratio?
  • What is the cost of a custom immunotoxin preparation? How long will it take to complete?

Recent Scientific References

Abstracts from Forum of European Neuroscience (FENS): July 13-17, Paris France

Abstracts from IASP 10th World Congress on Pain: August 17-22, San Diego California

Does 192-IgG-Saporin or 5,7-DHT kill cognitive functions in the rat? (continued from page 1)

Targeting Teaser Winners

Targeting Tools: Anti-Tac and Anti-Tac-SAP

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]

Targeting Trends Newsletter 02q3

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page.


Newsletter Highlights

  • Featured Antibodies (page 3 and page 4)
  • Neuropeptide Toxins (page 5)
  • Anti-Tac and Anti-Tac-SAP (page 7)

[fivecol_one]Page 1Page 2Page 3Page 4Page 5Page 6Page 7Page 8[/fivecol_one][fivecol_four_last]

Saporin Immunotoxins for Treating Human Hematological Malignancies (continued on page 2,6)

Contributed by David J Flavell, PhD, The Simon Flavell Leukaemia Research Unit, Division of Cancer Sciences, University of Southampton Medical School, United Kingdom.

www.leukaemiabusters.org.uk

Recent Scientific References

Featured Antibodies:

  • Antibody to Substance P (Cat. #AB-N10)
  • Antibody to VAChT (Cat. #AB-N11)

Targeting Talk: Neuropeptide Toxins

  • What are neuropeptide-toxins and how do they work?
  • Are neuropeptide-toxins effective suicide transport agents?

Targeting Ticklers (Jokes)

Targeting Teaser Winners from last issue

Targeting Tools: Anti-Tac and Anti-Tac-SAP

Targeting Technology Tutorial

Targeting Teaser (Jumble)

[/fivecol_four_last]